Citizens upgraded Iovance Biotherapeutics (IOVA) to Outperform from Market Perform with a $5 price target The company reported 30% sequential revenue growth in Q4 and highlighted progress across its network and manufacturing operations that suggest many early of the launch issues may be largely behind it, the analyst tells investors in a research note. The firm sees a “data-rich year” in 2026 for Iovance. It views the shares as undervalued at current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan
- Iovance Biotherapeutics: Strengthening Commercial Momentum and Expanding Amtagvi Runway Support Buy Rating
- Midday Fly By: Home Depot reports Q4 beat, AMD and Meta expand partnership
- Unusually active option classes on open February 24th
- Iovance Highlights Amtagvi Revenue Growth and Profitability Path